CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the role of the APOBEC3A enzyme in drug resistance in pancreatic cancer. It aims to understand how this enzyme contributes to genomic instability and treatment resistance, with the goal of identifying new therapeutic targets.
Pancreatic cancer is predicted to become the third leading cause of cancer-related death in Europe.
Drug resistance to even the most effective anti-cancer-targeted therapies constitutes a major contributor to poor prognosis in pancreatic ductal adenocarcinoma (PDAC).
Kirsten rat sarcoma virus (KRAS) mutations are found in >90% of PDAC, being an important oncogenic driver.
Although KRAS-targeted therapies have the potential to transform the clinical management of PDAC drastically, only a subset o…
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
